annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 6E Outcomes differences in tumors < 1 cm by age and breast cancer subtype.
(Abstract #580)
J. K. Litton, H. Chen, E. A. Mittendorf, F. Meric-Bernstam, M. Chavez-Mac Gregor,
W. A. Woodward, A. Sahin, R. L. Theriault, G. N. Hortobagyi, A. M. Gonzalez-
Angulo
Brd. 6F Adjuvant chemotherapy and lymph node irradiation in breast cancer patients
with axillary lymph node micrometastases or isolated tumor cells. (Abstract
#581)
M. Gardner, D. Stevens, S. Zilberman, S. Villette, F. Lerebours, P. Moisson,
B. De La Lande, R. Le Scodan, J. Guinebretiere, A. Labib
Brd. 6G Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with
breast-conserving surgery and radiation therapy (BCS�RT). (Abstract #582)
J. Goswami, S. Goyal, H. Wu, M. S. Moran, B. G. Haffty
Brd. 6H Cause-specific and all-cause mortality of HER2-positive, node-negative,
T1a and T1b breast cancers. (Abstract #583)
H. K. Chew, M. Brown
Brd. 7A Comorbidities’ impact on survival after treatment for early breast cancer.
(Abstract #584)
L. H. Land, S. O. Dalton, M. Jensen, M. Ewertz
Brd. 7B MDR1/ABCB1 single nucleotide polymorphism (SNP) as a possible
prognostic factor in breast cancer patients receiving docetaxel and
doxorubicin neoadjuvant chemotherapy. (Abstract #585)
H. Kim, B. Keam, S. Im, H. Ham, S. Han, D. Oh, W. Han, T. Kim, D. Noh, Y. Bang
Brd. 7C Correlation between quantitative HER2 protein level and pathologic complete
response (pCR) in HER2-positive (�) breast cancer patients (pts) treated with
neoadjuvant (NEO) dose-dense (dd) chemotherapy plus trastuzumab.
(Abstract #586)
J. Hurley, C. Welsh, A. C. Fort, J. Weidler, A. Paquet, W. Huang, Y. Lie, S. Gupta,
M. P. Bates, M. D. Pegram
Brd. 7D Do older patients with T1a lesions require sentinel lymph node biopsy?
(Abstract #587)
M. W. O’Malley, K. A. Griffith, M. S. Sabel, L. A. Newman, T. M. Breslin,
A. E. Chang, V. M. Cimmino, C. G. Kleer, K. M. Diehl
Brd. 7E Use of sequential FDG-PET/CT to guide extent of axillay lymph node
dissection in breast cancer receiving neoadjuvant chemotherapy. (Abstract
#588)
B. Keam, S. Im, Y. Koh, S. Han, D. Oh, K. Kang, T. Kim, I. Park, D. Noh, Y. Bang
Brd. 7F Predictors of pathologic response and correlation with long-term outcomes
in a trial of neoadjuvant concurrent paclitaxel radiation in locally advanced
breast cancer (LABC). (Abstract #589)
S. Adams, S. C. Lymberis, A. B. Chakravarthy, D. V. Spicer, T. Hochman,
M. Donach, J. D. Goldberg, R. Schneider, J. A. Pietenpol, S. Formenti
Brd. 7G The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant
chemotherapy for early breast cancer. (Abstract #590)
R. C. Leonard, D. Adamson, R. Anderson, R. Ballinger, G. Bertelli, R. E. Coleman,
L. Fallowfield, M. McLinden, J. Mansi, G. Thomas
Brd. 7H Obesity and tumor characteristics in nodal-positive early-stage breast
cancer: Results of the German ADEBAR study. (Abstract #591)
U. Andergassen, B. K. Rack, K. Annecke, H. Forstbauer, F. Ruhland, N. Harbeck,
H. L. Sommer, K. Friese, W. Janni, M. Kiechle
Brd. 8A Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary
breast cancer. (Abstract #592)
P. Schmid, C. Fleischmann, M. Wischnewsky, N. Syed, R. Shah, P. Quinlan,
L. Tooth, S. Kuemmel, A. M. Thompson, T. Crook
150